You are here

Study Evaluating CCI-779 and Letrozole in Post-menopausal Women With Breast Cancer

Last updated on February 20, 2019

FOR MORE INFORMATION
Study Location
Hoover, Alabama, 35216 United States
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Breast Neoplasms, Neoplasm Metastasis
Sex
Female
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Women aged greater than 18 years.

- Postmenopausal subjects

- Confirmed diagnosis of locally advanced (not amenable to curative surgery and/or
radiation) or metastatic breast cancer (Stage 3B or 4 respectively, by American Joint
Committee on Cancer Criteria)

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Extensive visceral disease

- Subjects with bone as the only site of disease

- Prior radiation therapy to the site of measurable disease for subjects with a solitary
measurable lesion

NCT00083993
Pfizer
Terminated
Study Evaluating CCI-779 and Letrozole in Post-menopausal Women With Breast Cancer

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Breast Neoplasms
NCT00471276
Females
18+
Years
Multiple Sites
Breast Neoplasms, Neoplasm Metastasis
NCT00067314
Females
18+
Years
Multiple Sites

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

Call Now